Boost Selectivity, Overcome Resistance & Leverage Combination Strategies for Safe & Efficacious Hippo Pathway Targeted Therapies Towards Clinical Success in Oncology, Regenerative Medicine & Beyond
November 20-21, 2024 | Virtual Summit
Welcome to the 3rd Hippo Pathway Targeted Drug Development Summit
Igniting Novel YAP, TAZ & TEAD Modulators Towards Clinical Validation
The field of Hippo Pathway targeted drugs is seeing a surge of activity, with new clinical data being generated everyday and novel combinations being tested. The 3rd Hippo Pathway Targeted Drug Development Summit has been built alongside industry experts from the likes of Vivace Therapeutics, Orion Pharma, Insilico Medicine and more to return as the premier event for Hippo industry leaders focusing on developing innovative, safe, and effective therapies in oncology, fibrosis, and beyond.
Join over 20 global Hippo experts as we advance YAP, TAZ, and TEAD modulators towards clinical success – right from the comfort of your screen! This is your virtual hub to meet 80+ Hippo experts from across the globe gathering for data-led presentations, deep-diving panels, and interactive roundtables to advance the Hippo industry forward.
Our World-Class Speaker Faculty for 2024 Includes:
Srinivas Vindo Saladi
Assistant Professor
University of Toledo, College of Medicine and Life Sciences
Brand New for 2024:
- Minimize Off-Target Toxicity: Optimize patient selection with the latest clinical data on Hippo-targeting drugs from Vivace Therapeutics and Crossignal Therapeutics
- Fast-Track Your IND Process: Delve into case studies showcasing in vivo efficacy in mesothelioma models and cutting-edge immunotherapy combinations from Insilico Medicine, Tyk Medicines, and Etern Therapeutics
- Master Hippo Pathway Inhibition: Discover breakthrough covalent drugs and targeted degraders from BridGene Bioscience and the University of Florida, aimed at achieving sustained Hippo pathway inhibition
- Unlock Powerful Combination Therapies: Uncover strategies to overcome Hippo-driven resistance to KRAS, MAPK, and EGFR inhibitors with insights from the University of Toledo and University of Torino
- Enhance Predictive Accuracy: Learn how preclinical models from Albany Medical College, University of Edinburgh, and Cleveland Clinic can reliably predict patient sensitivity and clinical outcomes
Other events in the Small Molecules & TPD World Series
